Breaking News Instant updates and real-time market news.

RARX

RA Pharmaceuticals

$15.39

0.69 (4.69%)

07:12
07/31/17
07/31
07:12
07/31/17
07:12

RA Pharmaceuticals receives orphan drug designation from FDA for RA101495

Ra Pharmaceuticals announced that the U.S. FDA has granted Orphan Drug Designation to RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria. Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases. RA101495, the company's lead clinical candidate, is a synthetic macrocyclic peptide inhibitor of complement component 5. The molecule is currently in Phase 2 clinical development as a self-administered subcutaneous injection for the treatment of PNH, a rare, chronic, life-threatening blood disorder where red blood cells are attacked and destroyed by the complement system. RA101495 received Orphan Drug Designation for the treatment of PNH in Europe in November 2016.

RARX RA Pharmaceuticals
$15.39

0.69 (4.69%)

06/27/17
JEFF
06/27/17
NO CHANGE
Target $25
JEFF
Buy
RA Pharmaceuticals selloff a buying opportunity, says Jefferies
Jefferies analyst Eun Yang says she's "encouraged' by the "clean" safety and tolerability as well as "clear" proof of concept reported for RA101495 reported this morning by RA Pharmaceuticals. The analyst is a buyer of the stock, especially on weakness. She says today's selloff may not necessarily be on the data, but on a lack of near-term catalysts with the next readout not expected to year-end 2017. Yang has a Buy rating on RA with a $25 price target.
04/18/17
FBCO
04/18/17
INITIATION
Target $19
FBCO
Outperform
RA Pharmaceuticals assumed with an Outperform at Credit Suisse
Target $19.
03/07/17
BMOC
03/07/17
NO CHANGE
BMOC
RA Pharmaceuticals price target raised to $31 from $24 at BMO Capital
BMO Capital analyst M. Ian Somaiya expects data from an open-label Phase II trial in PNH patients to show that the once daily subQ formulation of RA's RA101495 drug is viable and that the drug can compete effectively with Alexion's (ALXN) Soliris. Somaiya keeps an Outperform rating on RA.
01/05/17
JEFF
01/05/17
NO CHANGE
JEFF
Celgene, Alkermes among Jefferies' top 2017 Biotech picks
Jefferies' Biotechnology equity research team laid out their top picks for 2017. Following a volatile two years, the biotech space seeks to achieve "greater equilibrium" in 2017, the analysts write in a research note. They cite increasing competition, slowing volumes, and ramping payer leverage as reasons to remain selective when picking stocks this year and beyond. Among large-caps, Jefferies likes Celgene (CELG) for its "best-in-class growth" and sees limited downside in Gilead (GILD) shares. In the mid-cap space, the firm favors Alkermes (ALKS) given the prospects for Vivitrol and Aristada and a "strong" neurology pipeline as well as Vertex (VRTX). Jefferies' top small-cap picks include Aevi Genomics Medicine, Alder Biopharmaceuticals (ALDR), AMAG Pharmaceuticals (AMAG), DBV Technologies (DBVT), Immunomedics (IMMU), Ignyta (RXDX), Karyopharm (KPTI), RA Pharmaceuticals (RARX), TherapeuticsMD (TXMD) and Xenon Pharmaceuticals (XENE).

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.